May 3, 2018
Purdue researchers create a new instrument to rapidly test whether drugs contain trace crystallinity
WEST LAFAYETTE, Ind. – Researchers at Purdue University have created a device that can quickly and inexpensively determine whether new pharmaceutical formulations have trace crystallinity that can negatively impact the drug’s stability and bioavailability.
The researchers have developed instrumentation that can accurately detect in early stages whether a pharmaceutical formulation has trace crystalline content. The instrument is based off of triboluminescence and works by measuring light emitted when a pharmaceutical powder is crushed.
“Any light that is measured is directly proportional to how much crystallinity is in the formulation,” said Casey Smith, a graduate student in Purdue's Department of Chemistry.
The solid form of an active pharmaceutical ingredient can profoundly influence the proportion of that drug that can enter the body and have an effect. Many new drug candidates have low aqueous solubility, which leads to a lower bioavailability. If a drug doesn’t dissolve in a timely manner, it can pass through a body before it has had time to take effect. One method to overcome this problem is to put the drug into an amorphous state, or cast into a polymer matrix that readily dissolves in water.
“New drugs that are coming out are increasingly larger and more hydrophobic, or do not dissolve easily in water,” said Garth Simpson, a Purdue chemistry professor. “If crystallinity is detected, there's a good chance that it won't dissolve in a time frame required to be bioavailable and efficacious.”
The triboluminescence instrument is designed to provide rapid screening of amorphous solid dispersions, formulations created to make drugs more efficacious. The instrument can detect crystallinity in levels as low as 140 parts per million. A video of how the triboluminescence instrument works can be seen at https://youtu.be/em4n0Q6mWjI.
The instrument was created in collaboration with the Department of Chemistry’s Jonathan Amy Instrumentation Facility. It is an electro-mechanical device that uses a solenoid to strike powder on a microscope slide. A photo multiplier tube beneath the slide measures the optical radiation resulting from the triboluminescence of the compound. The light isn’t visible to the naked eye. A motor moves the microscope slide down the line to probe a new area of the powder. The researchers obtained a provisional patent on the device with the help of Purdue’s Office of Technology Commercialization.
“This technique would be more like a prescreen off an assembly line in a factory where they’re making these drugs. They can send a small amount of the material into this instrument for triboluminescence measurements. If they get a positive outcome from the sample, then they can send it off for more rigorous testing,” said Scott Griffin, a Purdue chemistry graduate student.
Griffin and Smith, both students in Simpson’s lab, were the lead authors in a paper on triboluminescence published in the peer-reviewed journal Analytical Chemistry that included researchers from Merck & Co.
There are other ways to determine crystallinity, including a second harmonic generation process that uses a femtosecond pulsed laser that also was developed in Simpson’s lab. But the triboluminescence instrument is much simpler.
“It boils down to the earliest time point which crystallinity can be detected,” Simpson said. “We wanted to have something that would be a simple yes or no assessment that could be done on site. If something fails, it can be taken to a more advanced instrument to get a better sense of quantitative characterization.”
Simpson said a triboluminescence instrument also could be used to determine quickly whether changes in the way a drug is produced causes crystallinity.
There is still work to be done, Simpson said. The researchers want to be able to do similar crystallinity testing in slurries and are working on a flow cell to accomplish that.
“So for a lot of these drug cocktails, when you put it into water it starts out in an amorphous state but can spontaneously crystallize. We want tools that can characterize and measure that process,” he said.
The researchers also are trying to get a sense for what fraction of drug molecules and drug compounds are likely to be amenable to triboluminescence analysis.
The initial work on the said triboluminescence instrument was funded through a National Science Foundation grant. The Purdue Research Foundation provided funding for the initial prototype and Merck has helped fund the more recent work.
The triboluminescence instrument is available for licensing from the Office of Technology and Commercialization.
About Purdue Office of Technology Commercialization
The Purdue Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities. The office is managed by the Purdue Research Foundation, which received the 2016 Innovation and Economic Prosperity Universities Award for Innovation from the Association of Public and Land-grant Universities. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at email@example.com. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at firstname.lastname@example.org. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University.
Scott Griffin, email@example.com
Casey Smith, firstname.lastname@example.org
Note to Journalists: The research paper is available at: https://pubs.acs.org/doi/10.1021/acs.analchem.8b01112